Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today reported $3.7 billion revenue for the first quarter of 2022, down 8% from the corresponding quarter of 2021, and slightly below the analysts’ consensus of $3.75 billion. Non-GAAP earnings per share was $0.55, meeting the analysts’ forecast.
Teva cut its 2022 revenue forecast from $15.6-16.2 billion to $15.4-16 billion and its Copaxone sales forecast from $850 million to $750 million.
RELATED ARTICLES
In response, Teva’s share price is down 2.58% in premarket trading on the NYSE.
Teva president and CEO Kare Schultz said, We are pleased to continue resolving opioid-related litigations with recent settlements in Florida and Rhode Island including the provision of lifesaving opioid treatments and recovery medicines for those who need them.”
He continued: “While easing of Covid-19 related restrictions has led to positive momentum in our European business, we are seeing fluctuations of foreign exchange rates, and have therefore lowered our 2022 revenue outlook, while reaffirming our earnings and cash flow guidance.”
Published by Globes, Israel business news – en.globes.co.il – on May 3, 2022.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
